Clinically, the BRAF mutation is an enigmatic target in CRC, and regardless of MSI status, BRAF mutant metastatic CRCs (mCRCs) are considered a unique entity characterized by dismal prognosis (median overall survival of fewer than 12 months) that do not respond efficiently to both standard chemotherapy and to orally selective inhibitors of BRAFV600E [3]. This evidence concerns the gene BRAF and colorectal carcinoma.